News & Events

BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today that its program to issue immunology researcher grants worth a total of $100,000 will accept applications until August 31, 2006.

The “BD Biosciences Immunology Grants” will be awarded to three applicants who detail an innovative research project that will utilize BD Biosciences immunology research reagents. A team of distinguished scientists from academic and other research institutions head the panel that will determine the winners. BD Biosciences will honor two researchers with immunology research reagents valued at $25,000 each and one Grand Prize winner with immunology research reagents valued at $50,000. Applicants are encouraged to submit abstracts within the fields of cell signaling, stem cell research, immune function or cancer research, but proposals for research in other immunology fields will also be accepted.

“There are thousands of investigators with wonderful ideas that will advance the scientific understanding of disease. For many of them, funding limitations for research reagents can be a tremendous hurdle,” said Robert Balderas, VP, R&D, BD Biosciences. “These grants are an expression of BD’s continuing commitment to innovation in research and development.”

Interested researchers may apply online at www.bdbiosciences.com/grant. All applications must be received by August 31, 2006. The winner will be announced September 29, 2006. Terms and conditions apply.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***